TABLE 1.
Induction of neutralizing antibodies in mice with EAV-VRPs and whole EAV
| Immunogen | Immunization schedule (weeks) | Dose (IUa or TCID50b) | Weeks after primary immunization | Neutralizing antibody titersc of mouse no.:
|
|||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||||
| pVR21-GL VRP | Primary (0) | 6 × 105 | 3 | 0 | 0 | 0 | 0 |
| First boost (3) | 5 | 0 | 0 | 0 | 0 | ||
| Second boost (7) | 9 | 0 | 0 | 0 | 0 | ||
| pVR21-M VRP | Primary (0) | 6 × 106 | 3 | 0 | 0 | 0 | 0 |
| First boost (3) | 5 | 0 | 0 | 0 | 0 | ||
| Second boost (7) | 9 | 0 | 0 | 0 | 0 | ||
| pVR100-GL/M VRP | Primary (0) | 3.6 × 106 | 3 | 32 | 32 | 64 | 64 |
| First boost (3) | 5 | 512 | 512 | 512 | 512 | ||
| Second boost (7) | 9 | 2,048 | 1,024 | 2,048 | 2,048 | ||
| EAV ATCC strain | Primary (0) | 2 × 104b | N/Ad | NDe | ND | ND | ND |
| First boost (4) | N/A | ND | ND | ND | ND | ||
| Second boost (7) | 9 | 1,024 | 1,024 | 1,024 | 512 | ||
a
Infectious units as determined by immunoperoxidase staining of infected BHK-21 cells.
b
50% tissue culture infectious doses.
c
Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 cell monolayers against 200 50% tissue culture infective doses of virus.
d
N/A, not applicable.
e
ND, not determined.